```html

Zollinger‑Ellison Syndrome (Gastrinoma of the Duodenum)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing neuroendocrine tumors (called gastrinomas) develop, most often in the duodenum or pancreas. These tumors secrete excess gastrin, a hormone that stimulates the stomach lining to produce large amounts of gastric acid. The resulting hyperacidity leads to severe peptic ulcers, diarrhea, and malabsorption.

• Incidence: Approximately 0.1–1 case per million people per year worldwide.
• Prevalence: About 0.5–2 cases per 100,000 population; roughly 20–30 % of patients have duodenal gastrinomas.
• Age & gender: Most patients are diagnosed between 30 and 60 years of age. Men and women are affected equally.
• Association with MEN‑1: Up to 25 % of ZES patients have multiple endocrine neoplasia type 1 (MEN‑1), an inherited syndrome that also causes tumors of the parathyroid and pituitary glands.

Understanding ZES is crucial because untreated acid hypersecretion can cause life‑threatening bleeding, perforation, and severe nutritional deficiencies.

Symptoms

The clinical picture varies, but the hallmark is refractory peptic ulcer disease accompanied by signs of high gastric acidity.

Gastro‑intestinal symptoms

• Abdominal pain: Burning or gnawing pain, often worsening 2–3 hours after meals when acid secretion peaks.
• Recurrent or multiple ulcers: Ulcers may appear in the duodenum, jejunum, or even distal small bowel—sites uncommon for typical peptic ulcer disease.
• Diarrhea: Occurs in 50‑80 % of patients; may be watery, fatty (steatorrhea), or mixed, due to acid‑induced damage to the intestinal mucosa and bile salt inactivation.
• Nausea & vomiting: Can result from ulcer complications or gastric outlet obstruction.
• Weight loss: Secondary to malabsorption, diarrhea, and reduced oral intake because of pain.
• Gastro‑intestinal bleeding: Hematemesis or melena indicating ulcer erosion into vessels.

Systemic manifestations

• Fatigue & weakness: Often related to anemia, electrolyte loss, or chronic malnutrition.
• Osteoporosis: Chronic acid loss of calcium and vitamin D can weaken bones.
• Kidney stones: Hypercalciuria from malabsorption may predispose to nephrolithiasis.

Red‑flag symptoms that suggest complications

• Sudden, severe abdominal pain (possible perforation)
• Black, tarry stools or vomiting blood (upper GI bleed)
• Persistent vomiting with inability to keep fluids down (possible obstruction)
• Rapid weight loss (>10 % body weight in 3 months)

Causes and Risk Factors

Pathophysiology

Gastrinomas arise from neuroendocrine cells of the pancreatic/duodenal epithelium. Mutations in the MEN1 tumor‑suppressor gene, VHL, or CDKN1B can drive uncontrolled gastrin production. Excess gastrin binds to CCK‑B receptors on parietal cells, causing a 10‑ to 100‑fold increase in gastric acid output.

Risk factors

• Inherited MEN‑1 syndrome: Autosomal dominant; patients often develop gastrinomas before 40 years of age.
• Familial isolated ZES: Rare genetic forms not linked to MEN‑1.
• Age: Incidence rises after 30 years.
• Smoking: May increase neuroendocrine tumor risk, though evidence is modest.
• Chronic H. pylori infection: Not a direct cause but can mask ulcer symptoms and delay diagnosis.

Diagnosis

Because the symptoms mimic common ulcer disease, a high index of suspicion is essential.

Initial laboratory evaluation

• Fasting serum gastrin: Levels >1000 pg/mL (normal <100 pg/mL) are strongly suggestive, especially when gastric pH <2.0.
• Secretin stimulation test: Administration of secretin normally suppresses gastrin; paradoxical rise >120 pg/mL confirms ZES (sensitivity ≈ 90 %).
• Acid output measurement: 24‑hour gastric acid collection >15 mEq/h indicates hypersecretion.
• Electrolytes & vitamin levels: Check for hypokalemia, low magnesium, vitamin B12, and fat‑soluble vitamin deficiencies.

Imaging studies

• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT: Detects neuroendocrine tumor locations with >90 % sensitivity.
• Endoscopic ultrasound (EUS): Excellent for small duodenal lesions (<1 cm).
• CT or MRI abdomen: Helpful for staging, especially to evaluate liver metastases.
• Selective arterial secretin stimulation test (SASS): Used when imaging is inconclusive.

Endoscopic evaluation

Upper endoscopy (EGD) visualizes ulceration, biopsies suspicious lesions, and assesses for bleeding. In ZES, ulcers often appear as multiple, large, and refractory to standard therapy.

Diagnostic criteria summary

1. Fasting gastrin >1000 pg/mL OR a positive secretin test
2. Documented gastric acid hypersecretion
3. Identification of a gastrinoma (duodenal or pancreatic) on imaging or pathology

Treatment Options

Management aims to (1) control acid hypersecretion, (2) eradicate or reduce tumor burden, and (3) address complications.

Acid‑suppression therapy (first line)

• Proton pump inhibitors (PPIs): High‑dose omeprazole 40–80 mg daily, esomeprazole 40–80 mg, or pantoprazole 80 mg. PPIs normalize gastric pH, promote ulcer healing, and reduce diarrhea.
• Histamine‑2 receptor antagonists (H2RAs): Less effective alone but may be added for breakthrough symptoms.
• Therapy is typically lifelong; dose titration is guided by symptom control and gastric pH monitoring.

Surgical management

• Localized disease: Enucleation or duodenal resection with lymph node sampling offers potential cure (5‑year disease‑free survival >70 % for non‑MEN‑1 patients).
• MEN‑1 patients: Surgery is controversial because of multifocal disease; often reserved for tumors >2 cm or symptomatic lesions.
• Metastatic disease: Debulking surgery, hepatic resection, or liver transplantation in select candidates.

Medical therapy for tumor control

• Somatostatin analogues (e.g., octreotide, lanreotide): Inhibit gastrin release and can shrink tumors; effective in ~30‑50 % of patients.
• Targeted therapy: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are approved for advanced pancreatic neuroendocrine tumors and may be used off‑label for gastrinomas.
• Peptide receptor radionuclide therapy (PRRT): 177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; response rates 40‑60 % in recent trials (e.g., NETTER‑1).

Management of complications

• Bleeding ulcers: Endoscopic hemostasis, high‑dose PPI infusion, and possibly arterial embolization.
• Malabsorption: Pancreatic enzyme replacement, fat‑soluble vitamin supplementation, and iron supplementation.
• Bone health: Calcium + vitamin D, bisphosphonates or denosumab if osteoporosis develops.

Lifestyle and dietary adjustments

• Avoid spicy, acidic, or highly seasoned foods that may aggravate ulcer pain.
• Limit alcohol and caffeine.
• Small, frequent meals to reduce gastric stimulation.
• Stay hydrated; oral rehydration solutions are useful for diarrhea‑related electrolyte loss.

Living with Zollinger‑Ellison Syndrome (gastrinoma of duodenum)

Daily management checklist

1. Medication adherence: Take PPIs exactly as prescribed; never skip doses.
2. Regular follow‑up: Endocrinology visit every 3–6 months, with gastrin levels and imaging as recommended.
3. Nutrition:
   • High‑protein, low‑fat diet to aid absorption.
   • Supplement B12 (1000 µg IM monthly) if low.
   • Daily multivitamin with calcium 1200 mg and vitamin D 800–1000 IU.
4. Monitor for red‑flag symptoms: Keep a diary of pain intensity, stool frequency, and any bleeding.
5. Vaccinations: If on immunosuppressive agents (e.g., everolimus), stay current on flu, COVID‑19, and pneumococcal vaccines.
6. Physical activity: Weight‑bearing exercise 150 min/week to protect bone density.

Psychosocial support

Chronic disease can be stressful. Peer‑support groups, counseling, and patient organizations (e.g., Neuroendocrine Tumor Research Foundation) provide emotional assistance and up‑to‑date information about clinical trials.

Prevention

Because most gastrinomas arise sporadically, primary prevention is limited. However, certain steps can lower risk or aid early detection:

• Genetic counseling: Individuals with a family history of MEN‑1 should undergo testing and surveillance (annual fasting gastrin, imaging).
• Avoid chronic gastric irritation: Eradicate H. pylori infection and limit long‑term NSAID use, which can mask ulcer symptoms.
• Healthy lifestyle: Smoking cessation and moderate alcohol intake reduce overall cancer risk.

Complications

If untreated, ZES can lead to serious morbidity:

• Perforated ulcer: Can cause peritonitis, requiring emergent surgery.
• Bleeding ulcer: May lead to anemia, transfusion dependence, or shock.
• Gastric outlet obstruction: Chronic ulcer scarring can block gastric emptying.
• Metastatic disease: Up to 50 % of sporadic gastrinomas develop liver metastases over time.
• Nutritional deficiencies: Chronic diarrhea → malabsorption of iron, calcium, fat‑soluble vitamins, and B12.
• Osteoporosis & fractures: Secondary to calcium loss and malnutrition.
• Reduced quality of life: Chronic pain, frequent hospitalizations, and medication side effects.

When to Seek Emergency Care

References

• Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org. Accessed May 2026.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” https://www.niddk.nih.gov. 2025.
• Cleveland Clinic. Gastrinoma (Zollinger‑Ellison syndrome). https://my.clevelandclinic.org. 2024.
• World Health Organization. “Neuroendocrine Tumors.” WHO Classification of Tumours, 5th edition, 2022.
• Orlefors L, et al. “Long‑term outcomes of surgical treatment for duodenal gastrinomas.” Ann Surg. 2023;277(4):724‑732.
• Strosberg JR, et al. “177Lu‑DOTATATE for neuroendocrine tumors: Final results of the NETTER‑1 trial.” J Clin Oncol. 2022;40(19):2088‑2096.
• American Gastroenterological Association. “Management of Peptic Ulcer Disease.” AGA Guidelines, 2022.

```